Vaccinex Net Income 2017-2021 | VCNX

Vaccinex net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Vaccinex Annual Net Income
(Millions of US $)
2020 $-29
2019 $-32
2018 $-30
2017 $-22
2016 $-26
Vaccinex Quarterly Net Income
(Millions of US $)
2021-06-30 $-6
2021-03-31 $-7
2020-12-31 $-6
2020-09-30 $-9
2020-06-30 $-7
2020-03-31 $-7
2019-12-31 $-6
2019-09-30 $-8
2019-06-30 $-9
2019-03-31 $-9
2018-12-31 $-8
2018-09-30 $-7
2018-06-30 $-7
2018-03-31 $-8
2017-12-31 $-3
2017-09-30 $-6
2017-06-30 $-6
2017-03-31 $-7
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.056B $0.001B
Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76